There was a similar decrease in NT-proBNP levels with empagliflozin compared with placebo in patients with and without diabetes in the first weeks (Pinteraction at week 12=0.30; Figure S5); thereafter, this decrease tended to be greater in patients with diabetes (Pinteraction at week 52=0.03). The gene discussed is NPPB; the disease is diabetes mellitus.